Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR

Basit Öğe Kaydı
dc.authorid0000-0003-1895-7217en_US
dc.contributor.authorAtaman, Sebnem
dc.contributor.authorSurmeli, Zuhre Sari
dc.contributor.authorSunar, Ismihan
dc.contributor.authorOzdemirel, Erhan
dc.contributor.authorAkinci, Aysen
dc.contributor.authorBodur, Hatice
dc.contributor.authorAkgul, Ozgur
dc.contributor.authorAltan, Lale
dc.contributor.authorAltay, Zuhal
dc.contributor.authorAyhan, Figen
dc.contributor.authorBirtane, Murat
dc.contributor.authorSoy Bugdayci, Derya
dc.contributor.authorCapkin, Erhan
dc.contributor.authorCerrahoglu, Lale
dc.contributor.authorDuruoz, Mehmet Tuncay
dc.contributor.authorGunaydin, Rezzan
dc.contributor.authorGunendi, Zafer
dc.contributor.authorGurer, Gulcan
dc.contributor.authorBal, Ajda
dc.contributor.authorKacar, Cahit
dc.contributor.authorKaptanoglu, Ece
dc.contributor.authorKaya, Taciser
dc.contributor.authorKocabas, Hilal
dc.contributor.authorKotevoglu, Nurdan
dc.contributor.authorNas, Kemal
dc.contributor.authorRezvani, Aylin
dc.contributor.authorSen, Nesrin
dc.contributor.authorSendur, Omer Faruk
dc.contributor.authorYalcin, Peyman
dc.date.accessioned2024-07-12T21:45:06Z
dc.date.available2024-07-12T21:45:06Z
dc.date.issued2015en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractObjectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey. Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected. Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same. Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.en_US
dc.identifier.doi10.5606/ArchRheumatol.2015.5654
dc.identifier.endpage284en_US
dc.identifier.issn2148-5046
dc.identifier.issn1309-0283
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84949207430en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage271en_US
dc.identifier.trdizinid189349en_US
dc.identifier.urihttps://dx.doi.org/10.5606/ArchRheumatol.2015.5654
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7795
dc.identifier.volume30en_US
dc.identifier.wosWOS:000366027100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.publisherTURKISH LEAGUE AGAINST RHEUMATISMen_US
dc.relation.ispartofARCHIVES OF RHEUMATOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY00322
dc.subjectBiologic disease modifying anti-rheumatic drugsen_US
dc.subjectrheumatoid arthritisen_US
dc.subjectsynthetic disease modifying anti-rheumatic drugsen_US
dc.subjecttreatment recommendationsen_US
dc.titleTurkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLARen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu